José RIVERA Rivera, PhD

PhD
Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Pascual Parrilla, Murcia, Spain

JOSE RIVERA BRIEF CV
ORCID: 0000-0003-4225-6840
Education:
1986: Degree in Chemistry (Biochemistry), University of Murcia
1987: MSc, School of Medicine, University of Murcia
1990: PhD and Doctorate Degree, University of Valencia

Research career:
1987-1990 PhD Fellowship, ISCIII, Ministry of Health, Spain
1989 PhD student, Department of Gynecology, University of Oxford
1991-present Staff Chemist, Blood Transfusion Centre, Murcia, Spain
1993- present Associate professor (part time), School of Medicine, University of Murcia.
2015-(6 months): Visiting Investigator (ISCIII grant), Prof. Steve Watson Lab, School of Medicine, University of Birmingham, UK
2008- Present Founder and coordinator of the Spanish group of Inherited Platelet Disorder (GEAP)
2015-Senior investigator of the Murcia Institute of Biomedical research and of Spanish network of rare diseases (CIBERER)

Current position:
Staff Chemist, Blood Transfusion Centre, Murcia, Spain. Head of the Blood Component processing and Quality Management; Head of the Platelet Research group.

Main domain of research:
Inherited and acquired platelet disorders,

Research Support:
ISCIII-Ministry of Health, current Project PI20/00926 (2020-2023); EAHAD research project (collaboration with CIEMAT, Madrid) on gene therapy approach in GT (2020-2022); CIBERER, Ministry of Health research project (collaboration with CIEMAT, Madrid) on gene therapy approach in GT (2021-2023)
Most recent Publications in the IPD filed. (All publication available at https://orcid.org/0000-0003-4225-6840)
1. Src-related thrombocytopenia: a fine line between a megakaryocyte dysfunction and an immune-mediated disease. Palma-Baqueros V et al. Blood Adv. 2022 Mar 29:bloodadvances.2021005446. doi: 10.1182/bloodadvances.2021005446. Epub ahead of print. PMID: 35349645.
2. Expanding the genetic spectrum of TUBB1-related thrombocytopenia. Palma-Barqueros V et al , Blood Adv. 2021 Dec 28;5(24):5453-5467. doi: 10.1182/bloodadvances.2020004057.

Presentation(s):

• PB0334 - A novel R1162S variant in MYH9 alters the biochemical interactions and dynamics of NMMHC-IIA, induces severe macrothrombocytopenia and perturbs leukocyte function and cellular coherence

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• OC 59.4 - Novel variants in GALE caused syndromic macrothrombocytopenia disrupting thrombopoiesis and glycosylation

  Tuesday, July 12, 2022
  11:30 AM – 11:45 AM

• OC 64.5 - Effect of the DIAPH1 R1213* GOF variant in actin-dependent cytoskeleton organization in megakaryocytes

  Tuesday, July 12, 2022
  3:45 PM – 4:00 PM

• PB1245 - Uncommon arterial and venous thrombotic complications in Bernard Soulier Syndrome and Glanzmann Thrombasthenia patients

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1248 - Integrated diagnostic workflow in two siblings with albinism and suspected Hermansky-Pudlak syndrome

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM